Romvimza (vimseltinib, oral CSF1R inhibitor for TGCT)
Symptomatic tenosynovial giant cell tumor in adults for whom surgical resection would cause worsening functional limitation or severe morbidity. Oncology (tenosynovial giant cell tumor).
About Romvimza
Romvimza (vimseltinib) is an oral switch-control kinase inhibitor of CSF1R, the colony-stimulating factor 1 receptor. It is developed by Deciphera Pharmaceuticals, an Ono Pharmaceutical company, and is approved by the US FDA for adult patients with tenosynovial giant cell tumor (TGCT) for whom surgical resection would cause worsening functional limitation or severe morbidity. TGCT is a rare locally aggressive neoplasm of the joint, and CSF1R-driven macrophage recruitment is central to the tumor biology, which is what makes a selective CSF1R inhibitor a rational targeted therapy.
Romvimza is taken orally on a twice-weekly schedule rather than daily, which is unusual for an oncology kinase inhibitor and reflects the half-life of the molecule. It is positioned as a targeted alternative to surgical re-resection in eligible patients and joins pexidartinib (Turalio) as the second oral CSF1R inhibitor approved for TGCT in the United States.
For international patients, Romvimza is sourced by Reserve Meds from a DSCSA-compliant US specialty wholesaler with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Romvimza
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Romvimza for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Romvimza is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Romvimza in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Romvimza
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.